AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/16/24

2024-05-16 01:01:00 ET Summary Diamond Hill invests on behalf of clients through a shared commitment to its valuation-driven investment principles, long-term perspective, capacity discipline and client alignment. Markets were mostly positive in Q1 2024, with the ongoing notable ex...

An updated analysis showed that LUPKYNIS is a cost-effective treatment for lupus nephritis, on par with other interventions for diabetes, blood pressure, and hyperlipidemia in adult patients with active lupus nephritis (LN). Additional data on baseline demographics from the Enlight-LN registr...

A propensity analysis of ALMS, AURA-LV, and AURORA 1 suggested that initial therapy with LUPKYNIS plus standard of care reduced exposure to potential toxicities and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenol...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a firesi...

2024-05-06 14:15:24 ET Summary Eighteen new analysts joined in April. This article features summaries of their initial publications and recommendations, covering a wide range of companies across sectors including finance, technology, healthcare, and energy. Take a look to find...

2024-05-02 16:49:49 ET Summary AUPH reports Q1'24 net product revenues of $48.1M, representing a 13.6% increase from the previous quarter. AUPH's pipeline member AUR200 has not been shelved and could enter phase 1 studies in 2024 whether in AUPH's hands, or externally if the drug ...

2024-05-02 12:03:11 ET Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Conference Call May 02, 2024 08:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & Investor Relations Peter Greenleaf - Chief Executive Officer Joe Mi...

2024-05-02 10:45:03 ET Sabre Corp (SABR) SABR is trading UP for the last 5 days, and it at trading at $2.97 with volume of 2,856,606 and a one day change of $0.07 (2.42%). Sabre Corp has a 52-week low of 1.81 and a 52-week high of $5.77. The business's 50-day moving average price is...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-02 06:09:37 ET More on Aurinia Pharma Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024 Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed Aurinia Pharm...